RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Ruolo delle cellule della immunità innata nella patogenesi della malattia da Helicobacter pylori
• 2 - Carcinoma gastrico e infezione da Helicobacter pylori: importanza del genotipo, delle attività enzimatiche e del proteoma batterici e di fattori ospite-correlati, quali il polimorfismo genetico delle citochine infiammatorie e dei perossisomi e l'espressione di oncogeni, geni oncosoppressori e molecole d'adesione.
• 3 - MECCANISMI MOLECOLARI DI CHEMIOPREVENZIONE E CHEMIORESISTENZA NELLA CARCINOGENESI GASTRICA CORRELATA ALL'INFEZIONE DA HELICOBACTER PYLORI
• 4 - Nuove prospettive sull'immunità innata e l'immunoterapia.
• 5 - Un approccio biomolecolare per la patologia HHV8-associata e la sua possibile trasformazione neoplastica:
• 6 - Nuove conoscenze fisiopatologiche per nuove prospettive terapeutiche del colangiocarcinoma
• 7 - Nuove strategie immunomodulatorie nella Malattia di Graves: ruolo delle chemochine e delle cellule T regolatorie
• 8 - COMPLICANZE OSTETRICHE DA ANTICORPI ANTI-FOSFOLIPIDI: meccanismi patogenetici molecolari quali nuovi target terapeutici e marcatori prognostici.
• 9 - IMMUNITA' INNATA E MALATTIA CELIACA
• 10 - Ruolo dell'FGFR2 e di altri cofattori nell'etiopatogenesi di tumori epiteliali.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • PATOLOGIA GENERALE
  • ANATOMIA PATOLOGICA
  • MEDICINA INTERNA
• Area scientifico disciplinare: Scienze biologiche
  • FISIOLOGIA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Campania

Bibliografia

1. Montecucco C. et al. 2001. Living dangerously: how Helicobacter pylori survives in the human stomach. Nat. Rev. Mol. Cell. Biol. 2:457.
2. Suerbaum S., et al. 2002. Helicobacter pylori infection. N. Engl. J. Med. 347:1175.
3. Nomura A., et al. 1991. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N. Engl. J. Med. 325:1132.
4. Parsonnet J., et al. 1994. Helicobacter pylori infection and gastric lymphoma. N. Engl. J. Med. 330:1267.
5. Correa P. 1992. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 52:6735.
6. Fiocca R., et al. 1992. Helicobacter colonization and histopathological profile of chronic gastritis in patients with or without dyspepsia, mucosal erosion and peptic ulcer: a morphological approach to the study of ulcerogenesis in man. Virchows Archiv. A. Pathol. Anat. 420:489.
7. El-Omar E.M., et al. 2000. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398.
8. Coussens L.M., et al. 2002. Inflammation and cancer. Nature 420:860.
9. Dixon M.F., et al. 1996. Classification and grading of gastritis. Am. J. Surg. Pathol. 20:1161.
10. D’Elios M.M., et al. 1997. T helper 1 effector cells specific for Helicobacter pylori in the gastric antrum of patients with peptic ulcer disease. J. Immunol. 158:962.
11. Mai U.E.H., et al. 1992. Surface proteins from Helicobacter pylori exhibit chemotactic activity for human leukocytes and are present in the gastric mucosa. J. Exp. Med. 175:517.
12. Satin B., et al. 2000. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J. Exp. Med. 191:1467.
13. Betten A., et al. 2001. A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis. J. Clin. Invest. 108:1221.
14. Nishioka H., et al. 2003. The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils. Eur. J. Immunol. 33:840.
15. Crabtree J.E., et al. 1995. Induction of interleukin-8 secretion from gastric epithelial cells by a cagA negative isogenic mutant of Helicobacter pylori. J. Clin. Pathol. 48:967.
16. Shimoyama T., et al. 1998. Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis. J. Clin. Pathol. 51:765.
17. Phadnis S.H., et al. 1994. Pathological significance and molecular characterization of the vacuolating toxin gene of Helicobacter pylori. Infect. Immun. 62:1557.
18. Van Doorn N.E., et al. 1999. The inflammatory response in CD1 mice shortly after infection with a CagA+/VacA+ Helicobacter pylori strain. Clin. Exp. Immunol. 115:421.
19. Montemurro P., et al. 2001. Helicobacter pylori neutrophil-activating protein stimulates tissue factor and plasminogen activator inhibitor-2 production by human blood mononuclear cells. J. Infect. Dis. 183:1055.
20. Montemurro P., et al. 2002. The neutrophil-activating protein of Helicobacter pylori is a potent stimulant of mast cells. Eur. J. Immunol. 32:671.
21. Puls J., et al. 2002. Activation of Helicobacter pylori CagA by tyrosine phosphorylation is essential for dephosphorylation of host cell proteins in gastric epithelial cells. Mol. Microbiol. 43:961.
22. Owen R.J., et al. 2003. Investigation of the biological relevance of Helicobacter pylori cagE locus diversity, presence of CagA tyrosine phosphorylation motifs and vacuolating cytotoxin genotype on IL-8 induction in gastric epithelial cells. FEMS Immunol. Med. Microbiol. 6:135.
23. Papa A., et al. 2002. Role of Helicobacter pylori CagA+ infection in determining oxidative DNA damage in gastric mucosa. Scand. J. Gastroenterol. 37:409.
24. Malaviya R., et al. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381:77.
25. Genovese A., et al. 2003. Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human FcepsilonRI+ cells through interaction with the k light chains of IgE. J. Immunol. 170:1854.
26. Marone G., et al. 2000. Mast Cells and Basophils. Academic Press. San Diego.
27. Boesiger J., et al. 1998. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of Fcepsilon receptor I expression. J. Exp. Med. 188:1135.
28. Supajatura V., et al. 2002. VacA, a vacuolating cytotoxin of Helicobacter pylori, directly activates mast cells for migration and production of proinflammatory cytokines. J. Immunol. 168:2603.
29. Patella V., et al. 2000. HIV-1 gp120 induces IL-4 and IL-13 release from human FcepsilonRI+ cells through interaction with VH3 region of IgE. J. Immunol. 164:589.
30. de Paulis A., et al. 2004. Basophils infiltrate human gastric mucosa at sites of Helicobacter pylori infection, and exhibit chemotaxis in response to H.pylori-derived peptide Hp(2-20). J. Immunol. (in stampa).
31. Mochizuki A., et al. 2003. The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation. J. Allergy Clin. Immunol. 112:102.
32. Triggiani M., et al. 1991. Differential synthesis of 1-Acyl-2-Acetyl-sn-Glycero-3-Phosphocholine and Platelet-Activating Factor by human inflammatory cells. J. Immunol. 147:660.
33. Rosam A-C., et al. 1986. Potent ulcerogenic actions of platelet-activating factor on the stomach. Nature 319:54.
34. Bussolati B., et al. 2000. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am. J. Pathol. 157:1713.
35. De Falco S., et al. 2002. Structure and function of Placental Growth Factor. Trends Cardiovasc. Med. 12:241.
36. Keates S., et al. 1997. Helicobacter pylori infection activates NF-kappa B in gastric epithelial cell. Gastroenterology 113:1099.
37. Zarrilli R., et al. 1999. Molecular response of gastric epithelial cells to Helicobacter pylori-induced damage. Cell. Microbiol. 1:93.
38. Naumann M., et al. 2004. Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis. Trends Microbiol. 12:29.
39. Caputo R., et al. 2003 Helicobacter pylori VacA toxin up-regulates endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism. Clin. Cancer Res. 9:2015.
40. Fiocca R., et al. 1993. High incidence of Helicobacter pylori colonization in early gastric cancer and the possible relationship to carcinogenesis. Eur. J. Gastroenterol. Hepatol. 5:S2.
41. Solcia E., et al. 1996. Intestinal and diffuse gastric cancers arise in a different background of Helicobacter pylori gastritis through different gene involvement. Am. J. Surg. Pathol. 20:S8.
42. Ranzani G.N., et al. 1995. p53 gene mutations and protein nuclear accumulation are early events in intestinal type gastric cancer but late events in diffuse type. Cancer Epidemiology, Biomarkers Prevention 4:223.
43. Guilford P., et al. 1998. E-cadherin germline mutations in familial gastric cancer. Nature 392:402.
44. Saito H., et al. 2001. Angiogenesis, angiogenic factor expression and prognosis of gastric carcinoma. Anticancer Res. 21:4365.
45. Kitadai Y., et al. 2003. Helicobacter pylori infection influences expression of genes related to angiogenensis and invasion in human gastric carcinoma cells. Biochem. Biophys. Res. Com. 311:809.
46. Normark S., et al. 2003. Persistent infection with Helicobacter pylori and the development of gastric cancer. Adv. Cancer Res. 90:63.
47. Kepley C.L., et al. 2003. Environmental polycyclic aromatic hydrocarbons, benzo(a) pyrene (BaP) and BaP-quinones, enhance IgE-mediated histamine release and IL-4 production in human basophils. Clin. Immunol. 107:10.

Parole Chiave

HELICOBACTER PYLORI, ANGIOGENESI, BASOFILI, GASTRITE CRONICA, HP-NAP, MASTOCITI, NEUTROFILI, VACA